- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
FDA Clears Biocon's Insulin Factory in Malaysia
After a number of issues raised by the FDA about plant quality, Biocon has gotten clearance for its Malaysia insulin plant and now awaits FDA marketing authorization for Semglee, its insulin glargine agent.
After a few years struggling with quality issues at its new Malaysia plant, Biocon appears to be closer to getting its insulin glargine (Semglee) product on the market in the United States. The company announced that the FDA noted only voluntary improvements needed on the latest inspection of the facility.
This follows earlier receipt of Complete Response Letters and Form 483 notices, which indicate that essential improvements are needed to allow production.
The resolution of those issues and the just-announced plant clearance represent “an endorsement of our commitment to global standards of quality and compliance,” the company said in a release.
The latest inspection, in February 2020, appears to have come under the wire for Biocon, as in March the FDA announced that it would suspend foreign site inspections as a result of the coronavirus 2019 (COVID-19) pandemic.
“The inspection has been closed with a Voluntary Action Indicated classification in the Establishment Inspection Report,” Biocon said in a release.
“The closing of the USFDA Inspection of our Malaysia facility is an important milestone in our journey of developing insulin glargine for patients in the United States,” Biocon said.
The company has partnered with Mylan in the effort to bring the biologic to market. Mylan has previously filed an application for the product with the FDA under the 505(b)(2) new drug application pathway under the FD&C Act. Under a change in the Biologics Price Competition and Innovation Act, insulin applications will be reviewed as biologic license applications under section 351 of the Public Health Service Act.
The insulin glargine product is already authorized in the European and Australian markets, where it is sold under the brand name Semglee.
In 2019, the Malaysia plant received a certificate of good manufacturing practice from the European Medicines Agency’s Irish inspection authority.
The effort to get the Malaysia plant approved for production was the result of a manufacturing site change from Bangalore.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Aflibercept Biosimilar MYL-1701P Provides Equivalence in DME Therapy
November 27th 2024The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference aflibercept in treating diabetic macular edema (DME), offering a promising option for reducing treatment costs and improving global access to care for patients with DME.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
